Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Cancer Diagnostic Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Cancer Genomics Proteomics. 2024 Jan-Feb;21(1):88-101. doi: 10.21873/cgp.20432.
BACKGROUND/AIM: Recently, inactivating somatic mutations of SWI/SNF chromatin-remodeling genes in cancers have been reported. However, few studies have been performed regarding the immunological analysis of the tumor microenvironment (TME) in chromatin remodeling complex gene-mutated tumors. In the present study, we identified cancer patients harboring various mammalian SWI/SNF complex mutations and investigated the immunological features in those mutated cancers.
Cancer patients harboring any type of chromatin remodeling complex gene mutation were selected and clinicopathological features were compared between chromatin remodeling complex gene expression-low and expression-high groups. Specifically, expression levels of immune response-associated genes and cancer-associated genes were compared between the SMARCA4 expression-low and expression-high groups using volcano plot analysis.
Among cancers harboring PBRM1, SAMRACA4 and ARID2 gene mutations, T-cell marker and mature B-cell marker genes were up-regulated in the tumor. Specifically, T-cell effector genes (CD8B, CD40LG), central memory marker genes (CD27, CCR7) and mature B-cell marker genes (CD20, CD38, CD79 and IRF4) were up-regulated, and cancer-associated genes including MYB, MYC and AURKB genes were down-regulated in the SMARCA4 expression-low group. Remarkably, heatmap of gene expression and immunohistochemistry (IHC) data demonstrated that the tertiary lymphoid structure (TLS) gene signature of mature B cells was up-regulated in SMACA4 gene-mutated stomach cancers.
These results suggest that immune tumor microenvironment status, such as mature B cell recruitment featuring the TLS gene signature and immune activation mediated by cancer signal down-regulation, might contribute to the classification of SMARCA4 gene-mutated tumors as immune checkpoint blockade therapy-sensitive target tumors.
背景/目的:最近,在癌症中发现了 SWI/SNF 染色质重塑基因的体细胞失活突变。然而,关于染色质重塑复合物基因突变肿瘤的肿瘤微环境(TME)的免疫分析研究甚少。在本研究中,我们鉴定了携带各种哺乳动物 SWI/SNF 复合物突变的癌症患者,并研究了这些突变癌症的免疫特征。
选择携带任何类型染色质重塑复合物基因突变的癌症患者,并比较染色质重塑复合物基因低表达和高表达组之间的临床病理特征。具体而言,使用火山图分析比较 SMARCA4 低表达和高表达组之间免疫反应相关基因和癌症相关基因的表达水平。
在携带 PBRM1、SAMRACA4 和 ARID2 基因突变的癌症中,肿瘤中 T 细胞标志物和成熟 B 细胞标志物基因上调。具体而言,上调了 T 细胞效应基因(CD8B、CD40LG)、中央记忆标志物基因(CD27、CCR7)和成熟 B 细胞标志物基因(CD20、CD38、CD79 和 IRF4),下调了癌症相关基因,包括 MYB、MYC 和 AURKB 基因在 SMARCA4 低表达组中。值得注意的是,基因表达和免疫组化(IHC)数据的热图表明,成熟 B 细胞的三级淋巴结构(TLS)基因特征在 SMACA4 基因突变的胃癌中上调。
这些结果表明,免疫肿瘤微环境状态,如成熟 B 细胞募集特征性的 TLS 基因特征和癌症信号下调介导的免疫激活,可能有助于将 SMARCA4 基因突变肿瘤分类为免疫检查点阻断治疗敏感的靶标肿瘤。